Reference doses, frequency, cycle lengths, washout periods and interactions. Tap any compound for full detail.
Escalate in 4-week phases. Slow titration limits GI distress and protects receptor sensitivity. Appetite suppression builds over weeks.
Never combine with other GLP-1/GIP agonists. Hypoglycaemia risk alongside insulin/sulfonylureas. Delays gastric emptying — affects oral absorption.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Mandatory 4-week escalation steps. Dual incretin action gives stronger appetite control than semaglutide. Nausea common early in each step-up.
Do not stack with other incretin mimetics. Caution with diabetic medication (hypoglycaemia).
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Most potent of the incretin class. Strict escalation essential. Elevated resting heart rate commonly reported during titration.
Never combine with other GLP-1/GIP/glucagon compounds. Monitor closely with any glucose-lowering medication.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Amylin pathway complements GLP-1 satiety signalling. Frequently paired with semaglutide.
Synergistic with GLP-1 agonists; titrate both slowly to manage nausea.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Pre-combined cagrilintide + semaglutide targeting two satiety pathways at once.
Do not add further incretin or amylin compounds.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Glucagon component adds an energy-expenditure angle. Strict escalation required.
No other incretin compounds concurrently.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Dual agonist following the standard slow-escalation framework.
No other incretin compounds concurrently.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Daily dosing rather than weekly. Weekly step-ups of 0.6 mg are typical.
Do not combine with other GLP-1 agonists.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Long-acting weekly GLP-1.
No other incretin agonists concurrently.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Native GLP-1 has a very short half-life; analogues (semaglutide etc.) are preferred for practical use.
No other incretin compounds concurrently.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Targets fat metabolism without affecting blood sugar or IGF-1.
Pairs with HGH Fragment 176-191. Generally well tolerated.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
NNMT inhibition supports fat-cell metabolism and cellular energy.
Limited interaction data — isolate to assess response.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Targets blood supply to fat tissue. Aggressive mechanism — limited human data; short defined cycles only.
Run in isolation. Monitor renal markers in research contexts.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Estrogen-related receptor agonist studied as an "exercise mimetic" for fat oxidation.
Early-stage compound; isolate.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Cosmetic fat-dissolving blend for localised adipose tissue.
Local injection only; expect swelling/tenderness at site.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Selective GH release with minimal cortisol/prolactin impact. Classic partner for CJC-1295. Dose away from food for the cleanest GH pulse.
Synergistic with a GHRH. Respect washout to protect pituitary function.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Also called Mod GRF 1-29. Mimics natural pulsatile GH release; short half-life suits multiple daily pulses.
Pair with a GHRP (ipamorelin) for potentiative synergy. Continuous use without washout suppresses endogenous output.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
DAC extends half-life to days, creating a sustained GH "bleed" rather than pulses.
Sustained elevation differs from pulsatile protocols — choose one approach, not both.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
The most common GH secretagogue stack, pre-blended for convenience.
Do not add additional GHRPs. Honour washout periods.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Potent GHRH well studied for visceral fat reduction.
Can be combined with a GHRP. Monitor IGF-1 over long cycles.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Gentle GHRH supporting sleep quality and recovery.
Synergistic with GHRPs.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Strong GH release; mild appetite stimulation and some cortisol/prolactin effect at higher doses.
Pair with a GHRH. Avoid combining multiple GHRPs.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Pronounced appetite stimulation via the ghrelin pathway — favoured in bulking research contexts.
Pair with a GHRH. Strong hunger response expected.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Most potent GHRP but desensitises receptors fastest — keep cycles short.
Rapid tolerance build-up; not for continuous use.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Sustained GH/IGF-1 elevation in oral form. Increases appetite and water retention; some report lethargy.
Can reduce insulin sensitivity — monitor fasting glucose over longer cycles.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Direct GH rather than a secretagogue. Start low to assess water retention and carpal-tunnel-type effects.
Affects insulin sensitivity. Understand combined IGF-1 load before stacking with secretagogues.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Extended-half-life IGF-1; researched for hypertrophy and recovery. Hypoglycaemia possible.
Keep fast carbs available (hypoglycaemia risk). Short cycles only.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Short-acting, often used site-specifically near trained muscle.
Hypoglycaemia risk. Short cycles.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
IGF-1 splice variant linked to muscle repair after mechanical load.
Often timed post-training. PEG-MGF version lasts longer.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Pegylation extends MGF half-life for systemic use.
Pairs with IGF-1 protocols in research contexts.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Fat-loss fragment of HGH; does not raise IGF-1 or affect glucose.
Pairs with AOD-9604. Best on an empty stomach.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Lipolytic-region fragment of growth hormone.
Best fasted; pairs with other fragments.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Binds and inhibits myostatin; researched for muscle growth. Short, intensive cycles.
Run isolated. Limited human data.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Activin receptor IIB inhibitor studied for muscle mass. Vascular side-effect signals in trials — caution.
Run isolated; monitor in research settings.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Reference compound in the myostatin pathway used in research.
Isolate.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
⚠️ Extremely high hypoglycaemia risk — mistakes can be fatal. Requires careful glucose management and is not a casual compound.
Severe hypoglycaemia risk, magnified by GH/IGF-1 compounds. Always have fast carbs available.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Extensively researched for tendon, ligament, gut and soft-tissue repair. Stable and well tolerated.
Commonly stacked with TB-500 for synergistic healing.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Promotes cell migration and systemic tissue repair.
Synergistic with BPC-157.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Pre-blended recovery stack covering both local and systemic repair.
No additional healing peptides usually needed.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Isolated active fragment of the thymosin beta-4 molecule.
Pairs with BPC-157.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Anti-inflammatory; researched for gut inflammation and skin conditions.
Pairs with BPC-157 for gut-focused protocols.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Cathelicidin peptide with antimicrobial and wound-modulating properties.
Can be pro-inflammatory at higher doses; start low.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Non-erythropoietic EPO fragment studied for neuropathic pain and tissue protection.
Does not raise haematocrit (unlike EPO).
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Potent opioid-receptor peptide researched for analgesia. High dependence/respiratory-depression risk profile.
⚠️ Opioid — do not combine with CNS depressants. Tolerance and dependence risk.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Parathyroid hormone fragment researched for bone density.
Monitor calcium in research settings.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Regulates metabolic homeostasis and exercise capacity.
Often run alone to gauge metabolic response.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
AMPK activation researched for endurance and glucose uptake.
Limited human data — isolate.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Binds cardiolipin on the inner mitochondrial membrane to support energy production.
Limited stacking data.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Supports fatty-acid transport into mitochondria for energy.
Generally well tolerated; timing around training is common.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
⚠️ Raises red-blood-cell production. Significant cardiovascular/clotting risk if haematocrit climbs — heavily monitored in any legitimate research setting.
High thrombosis risk. Requires haematocrit monitoring. Not a casual compound.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Neuroprotective, focus-enhancing; raises BDNF.
Frequently cycled alongside Selank.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Acetylated, amidated form with greater stability and potency than base Semax.
Pairs with NA Selank.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Calming and anxiolytic without sedation.
Complements Semax (focus + calm).
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Stabilised, more potent form of Selank.
Pairs with NA Semax.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Porcine-derived neurotrophic mixture used in pulsed courses.
Pulsed rather than continuous.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Extremely potent synaptogenic compound — researched at very small doses.
Potency means careful, low dosing; isolate.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Studied for neurogenesis and cognitive support.
Limited data; isolate.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
TREK-1 channel blocker researched for mood and neuroplasticity.
Isolate to assess.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Short peptide bioregulator targeting brain tissue; used in pulses.
Pulsed protocol.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Adamantane-based nootropic researched for neuroprotection and cognition.
Limited data; isolate.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Reference entry for the synaptogenic Dihexa family.
Very potent — low doses only.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Researched for sleep regulation and stress resilience.
Avoid combining with other sedative compounds.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Circadian-rhythm hormone for sleep timing. Lower doses often more effective than high.
Sedative; avoid stacking with other sleep agents without care.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Promotes wakefulness and alertness; researched intranasally.
Do not combine with stimulants carelessly.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Orexin-family wakefulness peptide.
As with Orexin A.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Immune-modulating thymic peptide.
Generally run in isolation.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Thymus-targeting bioregulator used in short pulsed courses.
Pulsed protocol.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Combination immune-support blend — verify constituents on the batch label.
Confirm components to avoid double-dosing a class.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Libido enhancement via central melanocortin pathways. Flushing/nausea at higher doses.
Caution with uncontrolled blood pressure. Transient BP rise reported.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Upstream regulator of GnRH; researched for reproductive hormone signalling and libido.
Isolate when assessing hormonal response.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Bonding/social neuropeptide; very short half-life.
Limited stacking data.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Tanning plus libido effects. Start very low to gauge nausea. Monitor moles.
Not for those advised against UV/tanning agents.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Prostaglandin E1 researched for erectile function.
Do not combine with other vasodilator ED agents.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Long-acting GnRH agonist; causes an initial flare then downregulation. Powerful hormonal effects.
⚠️ Significant HPTA impact — research-only, run with full understanding.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Pineal peptide researched for telomere maintenance; used in short intensive pulses 1–2× per year.
Run in isolation; pulsed rather than continuous.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Acetylated, amidated Epithalon variant for improved stability.
Pulsed protocol.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Cellular energy and DNA-repair cofactor. SubQ can sting — inject slowly. Flushing common.
Generally isolated.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Targets senescent ("zombie") cells for clearance. Aggressive mechanism; very limited human data — short pulses only.
Run isolated under research conditions. Not for continuous use.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Cytoprotective mitochondrial peptide researched for cellular resilience.
Limited data; isolate.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Short peptide bioregulator targeting cardiac tissue.
Pulsed protocol; bioregulators run in short courses.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Targets connective tissue.
Pulsed protocol.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Prostate-targeting peptide bioregulator.
Pulsed protocol.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Pancreatic tissue bioregulator.
Pulsed protocol.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Respiratory tissue bioregulator.
Pulsed protocol.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Targets respiratory epithelium.
Pulsed protocol.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Vascular-wall bioregulator.
Pulsed protocol.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Dipeptide bioregulator with immune-modulating research interest.
Pulsed protocol.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Bioregulator with liver and immune research focus.
Pulsed protocol.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Reproductive-system bioregulator.
Pulsed protocol.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Immune-system bioregulator.
Pulsed protocol.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Connective-tissue and cartilage bioregulator.
Pulsed protocol.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Stimulates endogenous testosterone production; used in restart/fertility research contexts.
Often combined with SERMs in HPTA-restart protocols.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Provides FSH/LH activity; researched in fertility contexts.
Used alongside HCG in some restart protocols.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Stimulates LH/FSH release; shorter-acting alternative to HCG.
Used in HPTA-support protocols.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Relaxin-derived peptide researched for anti-fibrotic and cardiovascular effects.
Limited data; isolate.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Collagen synthesis, skin remodelling and wound healing. Often used topically.
Avoid same-syringe mixing with sulphur-containing peptides (precipitation).
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Base GHK tripeptide without the copper complex.
As with GHK-Cu.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Combines copper-peptide skin remodelling with glutathione antioxidant support.
Self-contained skin blend.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Copper peptide researched for hair-follicle support and skin.
Avoid mixing with sulphur peptides.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
More selective tanning peptide than MT-2, with fewer libido/nausea effects.
Monitor skin/moles.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Cosmetic collagen-signalling peptide used in topical skincare.
Topical use; minimal systemic interaction.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Topical peptide marketed for expression-line softening.
Topical use.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Researched topically (often alongside valproic acid) for follicle neogenesis.
Topical research use.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Antioxidant supporting detox pathways and skin brightening.
Often paired with vitamin C in research protocols.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Hydration and dermal-volume support; cosmetic use.
Local/topical use.
Some research exists (often preclinical or small studies); human dosing data is limited. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
⚠️ Potent neurotoxin — administration requires trained professionals and precise dosing. Misuse is dangerous.
Do not combine with aminoglycoside-type agents that affect neuromuscular transmission.
Backed by human clinical trials and/or approved-drug literature. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Combination blend aimed at hair, skin and nail support — verify constituents on label.
Confirm components to avoid double-dosing.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Popular "glow" stack combining skin (GHK-Cu) and healing (BPC-157 + TB-500) peptides.
Self-contained — no need to add further healing/skin peptides.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Lower-strength GLOW blend.
Self-contained blend.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
GLOW plus KPV for an added anti-inflammatory angle.
Self-contained blend.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Multi-peptide performance blend — check exact constituents on the batch label before dosing.
Confirm components to avoid double-dosing the same class elsewhere.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.
Combination fat-loss blend — verify constituents on the label.
Avoid stacking with overlapping fat-loss compounds.
Dosing is based on aggregated community protocols, not clinical validation. Verify any figure yourself before relying on it — see our Sources & Methodology page for the databases to search.